

CSD/BM/SE/2025-2026  
January 29, 2026

**To**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400 001**

**To**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400 051**

**Scrip Code: 530239**

**Scrip Symbol: SUVEN**

Dear Sir/Madam,

**Sub: Outcome of the Meeting of Board of Directors of Suven Life Sciences Limited held on Thursday, January 29, 2026**

.....

Pursuant to the provisions of Regulation 30 of the SEBI (LODR) Regulations, 2015, as amended and other applicable provisions of law, we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. January 29, 2026, has *inter-alia* considered and approved the following along with other business matters.

**1. Allotment of 44,77,612 Equity Shares of the Company on preferential basis upon conversion 44,77,612 fully paid warrants**

The Board of Directors has approved the conversion of 44,77,612 fully paid warrants and issued & allotted 44,77,612 (Forty-four lakhs seventy-seven thousand six hundred and twelve) Equity Shares of Rs.1/- each to the following Non-Promoter Persons/ Entities at an issue price of Rs. 134/- per share on preferential basis in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

| <b>Sl. No.</b> | <b>Non-promoter persons/entities</b> | <b>No. of Equity shares allotted</b> |
|----------------|--------------------------------------|--------------------------------------|
| 1.             | 3P INDIA EQUITY FUND 1               | 33,58,209                            |
| 2.             | 3P INDIA EQUITY FUND 1M              | 11,19,403                            |
|                | <b>Total</b>                         | <b>44,77,612</b>                     |

Further we would like to inform that the Company has received from above said allottees 100% consideration amount aggregating to Rs. 60,00,00,008/- in compliance with SEBI (ICDR) Regulations, 2018.

**Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

Consequently, the paid-up equity share capital of the company stands increased to the following:

| <b>Particulars</b>                                 | <b>No. of Equity Shares</b> | <b>Amount in INR</b>    |
|--|-----------------------------|-------------------------|
| Pre-issue subscribed & paid-up capital             | 22,74,74,207                | 22,74,74,207.00         |
| <b>Post-issue subscribed &amp; paid-up capital</b> | <b>23,19,51,819</b>         | <b>23,19,51,819 .00</b> |

Disclosure required pursuant to Regulation 30 and Schedule III of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed herewith as **Annexure A**.

**2. Resignation of Mr. Shrenik Soni, Company Secretary & Compliance Officer (KMP) of the Company**

Board of Directors in its meeting held today took note of resignation tendered by Mr. Shrenik Soni (ICSI M. No.: F12400), Company Secretary & Compliance Officer (Key Managerial Personnel) of the Company, to pursue an alternate career opportunity and there is no other material reason. The resignation was accepted by the Board and recorded appreciation for the services rendered by Mr. Shrenik Soni during his tenure. Board then approved to relive him from his duties and all statutory/designated positions with effect from close of business hours on January 30, 2026. Copy of the resignation letter is enclosed with this letter.

Disclosure required pursuant to Regulation 30 and Schedule III of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed herewith as **Annexure B**.

**3. Appointment of Ms. Sangeetha Laxmi Kandari (ICSI M. No. A40736) as Company Secretary & Compliance Officer of the Company (Key Managerial Personnel)**

We wish to inform you that the Board of Directors at its meeting held today i.e. January 29, 2026, based on the recommendations of Nomination and Remuneration Committee held on January 29, 2026, considered and approved the appointment of Ms. Sangeetha Laxmi Kandari (ICSI M. No. A40736) as Company Secretary & Compliance Officer (Key Managerial Personnel) of the Company with effect from February 02, 2026.

Ms. Sangeetha Laxmi will also act as Compliance Officer of the Company as required SEBI (LODR) Regulations and SEBI (PIT) Regulations, 2015.

**Suven Life Sciences Limited**

In view of the above and pursuant to Regulation 30(5) of the SEBI LODR Regulations the contact details of Ms. Sangeetha Laxmi Kandari, authorized as KMP under the Company's Policy on criteria for determining the materiality for disclosure of events or information with effect from February 02, 2026, are as follows:

Suven Life Sciences Limited; Address: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad – 500034, Telangana.  
Tel. 040-2354 1142/1152; Email: sangeethak@suven.com

Disclosure required pursuant to Regulation 30 and Schedule III of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed herewith as **Annexure C**.

We request you to take these documents on your records.

The Board Meeting commenced at 11:30 AM IST and concluded at 12:40 PM IST.

Thanking you.  
Yours faithfully,  
For **Suven Life Sciences Limited**

**Shrenik Soni**  
Company Secretary & Compliance Officer

Encl.: as above

## **Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

**Annexure A**

**Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

| <b>Sl. no.</b>                       | <b>particulars</b>   | <b>details</b>   |                    |                                      |                                      |  |                        |           |                         |           |
|--------------------------------------|--|--|--------------------|--------------------------------------|--------------------------------------|--|------------------------|-----------|-------------------------|-----------|
| a)                                   | type of securities proposed to be issued (viz. equity shares, convertibles etc.);  | Fully paid-up equity shares upon conversion of warrants  |                    |                                      |                                      |  |                        |           |                         |           |
| b)                                   | type of issuance (further public offering, rights issue, depository receipts (ADR/ GDR), qualified institutions placement, preferential allotment etc.); | Preferential Allotment in accordance with Chapter V of the SEBI ICDR Regulations and other applicable law.   |                    |                                      |                                      |  |                        |           |                         |           |
| c)                                   | total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately);                            | 44,77,612 Equity Shares of face value of Rs. 1/- each pursuant to conversion of 44,77,612 warrants at an issue price of ₹ 134/- per warrant, for an aggregate consideration of Rs. 60,00,00,008/- to below allottees.  |                    |                                      |                                      |  |                        |           |                         |           |
| d)                                   | in case of preferential issue, the listed entity shall disclose the following additional details to the stock exchange(s):                               |  |                    |                                      |                                      |  |                        |           |                         |           |
|                                      | i. number of investors;  | 2  |                    |                                      |                                      |  |                        |           |                         |           |
|                                      | ii. names of the investors;  | <table border="1"> <thead> <tr> <th><b>Particulars</b></th> <th><b>No. of Equity Shares allotted</b></th> </tr> </thead> <tbody> <tr> <td><b>Non-promoter persons/entities</b></td> <td></td> </tr> <tr> <td>3P INDIA EQUITY FUND 1</td> <td>33,58,209</td> </tr> <tr> <td>3P INDIA EQUITY FUND 1M</td> <td>11,19,403</td> </tr> </tbody> </table> | <b>Particulars</b> | <b>No. of Equity Shares allotted</b> | <b>Non-promoter persons/entities</b> |  | 3P INDIA EQUITY FUND 1 | 33,58,209 | 3P INDIA EQUITY FUND 1M | 11,19,403 |
| <b>Particulars</b>                   | <b>No. of Equity Shares allotted</b>   |  |                    |                                      |                                      |  |                        |           |                         |           |
| <b>Non-promoter persons/entities</b> |  |  |                    |                                      |                                      |  |                        |           |                         |           |
| 3P INDIA EQUITY FUND 1               | 33,58,209  |  |                    |                                      |                                      |  |                        |           |                         |           |
| 3P INDIA EQUITY FUND 1M              | 11,19,403  |  |                    |                                      |                                      |  |                        |           |                         |           |
|                                      | iii. post allotment of securities - outcome of the subscription  | Pursuant to conversion, the issued, subscribed and paid-up equity share capital of the Company stands increased to Rs. 23,19,51,819/- consisting of 23,19,51,819 fully paid-up equity shares of Rs. 1/- each.  |                    |                                      |                                      |  |                        |           |                         |           |
|                                      | iv. issue price/ allotted price (in case of convertibles)  | Rs. 134/- per share  |                    |                                      |                                      |  |                        |           |                         |           |
|                                      | v. in case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument;   | Allotment of 44,77,612 equity shares pursuant to the conversion of warrants at an issue price of Rs. 134/- each (face value of Rs. 1/- each and premium of Rs. 133/- each) upon receipt of 100% consideration amount from above mentioned allottees amounting to Rs. 60,00,00,008/-.   |                    |                                      |                                      |  |                        |           |                         |           |
| e)                                   | any cancellation or termination of proposal for issuance of securities including reasons thereof.  | Not applicable   |                    |                                      |                                      |  |                        |           |                         |           |

**Suven Life Sciences Limited**

**Annexure B**

**Disclosure of information pursuant Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

| Sl. No | Particulars  | Details   |
|--------|--|---|
| 1)     | Reason for change viz. <del>appointment, re-appointment, cessation, removal, death or otherwise</del> resignation, | Mr. Shrenik Soni (ICSI Membership No.: F12400) has tendered his resignation from the position of Company Secretary & Compliance Officer (Key Managerial Personnel) of the Company vide resignation letter dated 11 <sup>th</sup> November, 2025, to pursue alternate career opportunity and there was no other material reason. |
| 2)     | Date of <del>appointment/</del> cessation (as applicable) & <del>term of appointment</del>                         | Mr. Shrenik Soni will cease to be Key Managerial Personnel of the Company, with effect from close of business hours on January 30, 2026.  |
| 3)     | Brief profile (in case of appointment)   | Not Applicable  |
| 4)     | Disclosure of relationships between directors (in case of appointment of a director)                               | Not Applicable  |

**Suven Life Sciences Limited**

## Resignation Letter

Date: 11/11/2025

To

**The Board of Directors**  
**Suven Life Sciences Limited,**  
6th Floor, SDE Serene Chambers,  
Road No 5, Banjara Hills,  
Hyderabad – 500 034

Dear Sir/Madam,

**Subject: Resignation from the position of Company Secretary and Compliance Officer of the Company**

With reference to the above-mentioned subject, I hereby tender my resignation as Company Secretary and Compliance Officer (KMP) and all other statutory/ designated positions in the Company, to pursue an alternate career opportunity and confirm that there is no other material reason.

I request you to relieve me of duties and responsibilities effective from close of business hours on January 30, 2026.

I hereby convey my sincere thanks to the Board of Directors and Management of the Company for their unstinted support and cooperation extended during my tenure as Company Secretary and Compliance Officer of the Company.

Thanking You,  
Yours Sincerely,



**Shrenik Soni**  
(ICSI Membership No.: F12400)

Received & approved  
30 Jan 2026  
WA 28

**Annexure C**

**Disclosure of information pursuant Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

| Sl. No | Particulars  | Details  |
|--------|--|--|
| 1)     | Reason for change viz. appointment, resignation, removal, death or otherwise         | Appointment of Ms. Sangeetha Laxmi Kandari (ICSI Membership No: A40736) as Company Secretary & Compliance Officer of the Company.  |
| 2)     | Date of appointment/ reappointment/ cessation (as applicable)                        | Appointment of Ms. Sangeetha Laxmi Kandari as 'Company Secretary and Compliance Officer'. She would take over as Company Secretary and Compliance Officer (Key Managerial Personnel) of the Company with effect from February 02, 2026.  |
| 3)     | term of appointment  | Not Applicable   |
| 4)     | Brief profile (in case of appointment)   | Ms. Sangeetha Laxmi (ICSI Membership No: A40736), is a qualified Company Secretary and a member of the Institute of Company Secretaries of India (ICSI) with Post-Graduation in Commerce. She is a seasoned corporate governance professional with more than 9 years of experience in Corporate, Secretarial, and Compliance function.<br>Prior to joining Suven, she was associated with Shilpa Biocare Pvt. Ltd, Avra Laboratories Pvt. Ltd and Prasad Media Corporation Pvt. Ltd. |
| 5)     | Disclosure of relationships between directors (in case of appointment of a director) | Not Applicable   |

**Suven Life Sciences Limited**